274 related articles for article (PubMed ID: 22750480)
1. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
[TBL] [Abstract][Full Text] [Related]
2. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
[TBL] [Abstract][Full Text] [Related]
3. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice.
Jaafari MR; Bavarsad N; Bazzaz BS; Samiei A; Soroush D; Ghorbani S; Heravi MM; Khamesipour A
Antimicrob Agents Chemother; 2009 Jun; 53(6):2259-65. PubMed ID: 19223613
[TBL] [Abstract][Full Text] [Related]
4. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
5. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation.
Schwartz J; Moreno E; Fernández C; Navarro-Blasco I; Nguewa PA; Palop JA; Irache JM; Sanmartín C; Espuelas S
Eur J Pharm Sci; 2014 Oct; 62():309-16. PubMed ID: 24964292
[TBL] [Abstract][Full Text] [Related]
6. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
7. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis.
Garnier T; Brown MB; Lawrence MJ; Croft SL
J Pharm Pharmacol; 2006 Aug; 58(8):1043-54. PubMed ID: 16872550
[TBL] [Abstract][Full Text] [Related]
8. Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.
Kavian Z; Alavizadeh SH; Golmohamadzadeh S; Badiee A; Khamesipour A; Jaafari MR
Acta Trop; 2019 Aug; 196():142-149. PubMed ID: 31103698
[TBL] [Abstract][Full Text] [Related]
9. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
[TBL] [Abstract][Full Text] [Related]
10. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
Schwartz J; Moreno E; Calvo A; Blanco L; Fernández-Rubio C; Sanmartín C; Nguewa P; Irache JM; Larrea E; Espuelas S
J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731
[TBL] [Abstract][Full Text] [Related]
11. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod.
El-On J; Bazarsky E; Sneir R
Exp Parasitol; 2007 Jun; 116(2):156-62. PubMed ID: 17306255
[TBL] [Abstract][Full Text] [Related]
12. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis.
Carneiro G; Santos DC; Oliveira MC; Fernandes AP; Ferreira LS; Ramaldes GA; Nunan EA; Ferreira LA
J Liposome Res; 2010 Mar; 20(1):16-23. PubMed ID: 19530897
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis.
Mussi SV; Fernandes AP; Ferreira LA
Parasitol Res; 2007 May; 100(6):1221-6. PubMed ID: 17206508
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
15. Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
Gonçalves GS; Fernandes AP; Souza RC; Cardoso JE; de Oliveira-Silva F; Maciel FC; Rabello A; Ferreira LA
Acta Trop; 2005 Feb; 93(2):161-7. PubMed ID: 15652330
[TBL] [Abstract][Full Text] [Related]
16. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
Grogl M; Schuster BG; Ellis WY; Berman JD
J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319
[TBL] [Abstract][Full Text] [Related]
17. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607026
[TBL] [Abstract][Full Text] [Related]
20. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
Garnier T; Mäntylä A; Järvinen T; Lawrence J; Brown M; Croft S
J Antimicrob Chemother; 2007 Oct; 60(4):802-10. PubMed ID: 17715126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
